Similar articles

• Correction to Lancet Oncol 2015; 16: 324. High-dose radiotherapy with shortterm or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

  Zapatero A, Guerrero A, Maldonado X. Zapatero A, et al. Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70272-X. Epub 2015 May 27. Lancet Oncol. 2015. PMID: 26065609 No abstract available.
• Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

  Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M. Gravis G, et al. Lancet Oncol. 2013 Feb;14(2):149-58. doi: 10.1016/S1470-2045(12)70560-0. Epub 2013 Jan 8. Lancet Oncol. 2013. PMID: 23306100 Clinical Trial.
• Correction to Lancet Oncol 2014; 15: 1324. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis.

  Ndiaye C, Mena M, Alemany L. Ndiaye C, et al. Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70270-6. Epub 2015 May 27. Lancet Oncol. 2015. PMID: 26065610 No abstract available.
• American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.

  Basch EM, Somerfield MR, Beer TM, Carducci MA, Higano CS, Hussain MH, Scher HI; American Society of Clinical Oncology. Basch EM, et al. J Clin Oncol. 2007 Nov 20;25(33):5313-8. doi: 10.1200/JCO.2007.13.4536. Epub 2007 Oct 9. J Clin Oncol. 2007. PMID: 17925542 Review.
• Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.

  Gravis G, Audenet F, Irani J, Timsit MO, Barthelemy P, Beuzeboc P, Fléchon A, Linassier C, Oudard S, Rebillard X, Richaud P, Rouprêt M, Thiery Vuillemin A, Vincendeau S, Albiges L, Rozet F. Gravis G, et al. Cancer Treat Rev. 2017 Apr;55:211-217. doi: 10.1016/j.ctrv.2016.09.008. Epub 2016 Sep 10. Cancer Treat Rev. 2017. PMID: 27665366 Review.